Classes | Virtual Medical Academy

Viewing 20 results

You are viewing the category of Dermatology

Dermatology

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

By :

Prof.Vimal Prajapati

Dermatology

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

By :

Prof.Vimal Prajapati

Dermatology

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

By :

Lilly Saudi Arabia

Dermatology

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

By :

Lilly Saudi Arabia

Dermatology

Assessing Subjective Burden in Patients with Atopic Dermatitis

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Assessing Clinical Severity in Patients with Atopic Dermatitis

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Assessing lack of treatment response in patients with Atopic Dermatitis

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

By :

Dr. Sarina Elmariah

Dermatology

The AD Saga Measuring Eligibility for Systemic Therapy

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Taltz have Connected Clinical trials with Real World Evidence (RWE)

By :

Dr.Yousef Binamer

Dermatology

Taltz in the real-world: Month12 out comes from the PSoHO study.

By :

Lilly Saudi Arabia

Dermatology

Treating severe AA with Olumiant (patient case)

By :

Dr. Sergio Galván

About Us

Support

Technical Requirements

VMA Team

Partner

You are viewing the category of Dermatology

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

Assessing Subjective Burden in Patients with Atopic Dermatitis

Assessing Clinical Severity in Patients with Atopic Dermatitis

Assessing lack of treatment response in patients with Atopic Dermatitis

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

The AD Saga Measuring Eligibility for Systemic Therapy

Taltz have Connected Clinical trials with Real World Evidence (RWE)

Taltz in the real-world: Month12 out comes from the PSoHO study.

Treating severe AA with Olumiant (patient case)

Call Center 920008161

[email protected]